Evaluation of the Impact of Rehabilitation Strategies and Early Discharge After Respiratory Failure
Launched by HOSPITAL ISRAELITA ALBERT EINSTEIN · Mar 26, 2024
Trial Information
Current as of August 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how specific rehabilitation strategies and early discharge from the hospital can improve the recovery of patients who have experienced severe breathing problems due to suspected COVID-19. The goal is to see if these strategies can help patients feel better both in the short and long term, focusing on their quality of life after being treated in the Intensive Care Unit (ICU), during their hospital stay, and after they go home.
To participate in the trial, you need to be at least 18 years old and required to stay in the ICU because of serious breathing issues related to COVID-19, which may include the use of a breathing machine. The trial is not yet recruiting participants, but it’s important to know that those with very serious underlying health conditions or communication challenges may not be eligible. If you join, you can expect to receive support and follow-ups through phone calls to help track your recovery progress.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age of at least 18 years
- • 2. Need for ICU admission due to hypoxemic acute respiratory failure with suspected COVID-19
- • 3. Need for invasive mechanical ventilation.
- Exclusion Criteria:
- • 1. Severe underlying disease with a life expectancy of less than 3 months;
- • 2. Absence of a responsible family member for cases of patients with communication difficulties (aphasia, severe cognitive impairment, non-native speakers of Portuguese);
- • 3. Absence of telephone contact;
- • 4. Participants already included in the study;
- • 5. Unavailability to carry out telephone follow-ups.
About Hospital Israelita Albert Einstein
Hospital Israelita Albert Einstein is a leading healthcare institution in Brazil, renowned for its commitment to excellence in patient care, education, and research. As a prominent clinical trial sponsor, the hospital emphasizes innovation and scientific advancement, facilitating cutting-edge studies across various medical disciplines. With a state-of-the-art infrastructure and a dedicated team of professionals, Hospital Israelita Albert Einstein fosters collaboration with global research networks to enhance clinical outcomes and contribute to the advancement of medical knowledge. The institution is dedicated to adhering to the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Adriano Pereira
Study Chair
Hospital Israelita Albert Einstein
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported